Amphastar Pharmaceuticals Inc (AMPH, Financial) files its latest 10-K with SEC for the fiscal year ended on December 31, 2017. Amphastar Pharmaceuticals Inc is a specialty pharmaceutical company engaged in developing, manufacturing, marketing and selling generic and proprietary injectable & inhalation products. Its products are used in hospitals or urgent care clinical settings. Amphastar Pharmaceuticals Inc has a market cap of $935.606 million; its shares were traded at around $20.35 with a P/E ratio of 226.11 and P/S ratio of 4.08.
For the last quarter Amphastar Pharmaceuticals Inc reported a revenue of $60.4 million, compared with the revenue of $63.54 million during the same period a year ago. For the latest fiscal year the company reported a revenue of $240.2 million, a decrease of 5.9% from the previous year. For the last five years Amphastar Pharmaceuticals Inc had an average revenue growth rate of 3.8% a year.
The reported diluted earnings per share was 9 cents for the year, a decline of 59.1% from the previous year. The Amphastar Pharmaceuticals Inc had an operating margin of -0.37%, compared with the operating margin of 6.15% a year before. The 10-year historical median operating margin of Amphastar Pharmaceuticals Inc is 1.71%. The profitability rank of the company is 5 (out of 10).
At the current stock price of $20.35, Amphastar Pharmaceuticals Inc is traded at 41.1% premium to its historical median P/S valuation band of $14.42. The P/S ratio of the stock is 4.08, while the historical median P/S ratio is 2.89. The stock gained 38.06% during the past 12 months.
For the complete 20-year historical financial data of AMPH, click here.
